| Document |
Document Title |
|
WO/2022/200442A1 |
Immunoresponsive cells comprising an NKG2D polypeptide and a CXCR2 polypeptide, and, optionally, a fusion polypeptide comprising a DNAX-activating 10 (DAP10) polypeptide and a DNAX-activating protein 12 (DAP12) polypeptide, are provided....
|
|
WO/2022/199603A1 |
An antibody fusion protein comprising: i) a multivalent (e.g., bivalent) antibody or antigen-binding fragment thereof specifically recognizing Angiopoietin-2 (Ang2) ( "multivalent anti-Ang2 antibody or antigen-binding fragment thereof" )...
|
|
WO/2022/204282A1 |
An aspect of the invention provides nucleic acids comprising a nucleotide sequence encoding chimeric antigen receptor (CAR) amino acid constructs. Polypeptides, recombinant expression vectors, host cells, populations of cells, and pharma...
|
|
WO/2022/197620A1 |
Provided herein is a fusion protein comprising: (a) an extracellular domain comprising a first binding moiety that is capable of specifically binding to a first cell surface marker; (b) a transmembrane domain; and (c) an intracellular do...
|
|
WO/2022/192974A1 |
The present invention pertains to the field of biotechnology and immunology and relates to immunogenic peptide combinations, chimeric peptides, compositions comprising same and uses thereof for controlling ticks, especially ticks of the ...
|
|
WO/2022/198001A1 |
Disclosed herein are methods using sEphB4-HSA an effective first-line therapy for cancers where current therapies are ineffective, result in relapse, or are not even considered for use due to the type of cancer and related tumors.
|
|
WO/2022/197963A1 |
The subject matter described herein is directed to pharmaceutical compositions comprising a long-acting recombinant human growth hormone, and their use in growth-related disorders, methods of making, dosage forms, and uses thereof. In an...
|
|
WO/2022/194224A1 |
A cell comprising a mutant protein, the mutant protein causing the cell to be insensitive toward an inhibitor which affects the activity and/or killing function thereof; a universal chimeric antigen receptor T cell which is related to th...
|
|
WO/2022/196719A1 |
The present invention provides: a chimeric receptor polypeptide which is useful in treatment of myasthenia gravis and in which an extracellular domain that includes an antigenic region linkable to an anti-human nicotinic acetylcholine re...
|
|
WO/2022/194403A1 |
The present invention relates to polypeptides comprising a first amino acid sequence comprising one or more GG repeat sequences and a peptide or polypeptide of interest in form of a fusion protein that exhibits increased renaturation eff...
|
|
WO/2022/194260A1 |
Provided are use of FGF21 polypeptide, FGF21 fusion protein or dual-fusion protein of FGF21 polypeptide and GLP-1 or a functional variant thereof in the manufacture of a medicament for treating fatty liver-related diseases.
|
|
WO/2022/195629A1 |
The present invention provides engineered arginase construct preferably engineered human arginase (EHA) polypeptide constructs comprising human arginase 1 polypeptide fused to non-arginase polypeptides via a linker peptide. The invention...
|
|
WO/2022/197961A1 |
The subject matter described herein is directed to methods of treating growth hormone related disorders by administering a long-acting recombinant human growth hormone. In another embodiment, a long-acting recombinant human growth hormon...
|
|
WO/2022/197764A2 |
Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1),...
|
|
WO/2022/196683A1 |
Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. A serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxi...
|
|
WO/2022/194067A1 |
Disclosed in the present invention are an anti-BAFFR antibody or an antigen-binding fragment thereof, a use thereof, and a pharmaceutical composition. The anti-BAFFR antibody provided by the present invention can specifically bind to BAF...
|
|
WO/2022/197819A1 |
The present disclosure provides compositions of matter comprising a polymer or peptide bound to an oxidized amino acid or an analog thereof. The present disclosure also provides packaging materials, consumer products, and cosmetic produc...
|
|
WO/2022/187961A1 |
The present technology generally relates to a microorganism displaying antigenic proteins of the SARS-CoV2 coronavirus on its surface, to methods of preparing same, to composition comprising such microorganism and to methods for treatmen...
|
|
WO/2022/191253A1 |
A method for producing a fusion protein comprising BDNF and an anti-transferrin receptor antibody or a fragment thereof, the method comprising a step for culturing a transformed mammalian cell containing a gene encoding the fusion protei...
|
|
WO/2022/191742A1 |
An invention relates to medicine, molecular biology, pharmaceuticals and can be used for the diagnostics of immunity to coronavirus infection. A method for assessment of the cellular immune response against coronavirus infection is propo...
|
|
WO/2022/192170A1 |
This disclosure relates to scaffolds for inducing antibody responses against antigenic sites. In certain embodiments, this disclosure relates to compositions and methods using a filovirus sGP as a scaffold for inducing antibody responses...
|
|
WO/2022/191223A1 |
The present invention addresses the problem of, in a method for extracting a target protein from prokaryotic cells expressing the target protein, preventing the contamination of the target protein with foreign substances and increasing t...
|
|
WO/2022/191158A1 |
Disclosed is a method for producing a fusion protein in which an antibody is fused with a lysosomal enzyme. This method for producing a fusion protein in which an antibody is fused with a human lysosomal enzyme comprises: (a) culturing m...
|
|
WO/2022/188816A1 |
An improved CG base editing system, which can realize efficient and accurate in-vivo C-to-G base editing.
|
|
WO/2022/188865A1 |
Provided are a bifunctional molecule capable of binding to human transforming growth factor β (TGFβ) and human programmed death ligand 1 (PD-L1), a pharmaceutical composition thereof, and a use thereof in the treatment of cancer. The b...
|
|
WO/2022/188883A1 |
The present invention provides a preparation method and use of a TNFR2 and APRIL/BAFF receptor protein fusion. Specifically, the present invention provides a fusion protein, the fusion protein comprising a TNFR2 extracellular segment and...
|
|
WO/2022/188764A1 |
Disclosed is a preparation method for NK cells having low expression of CD7. The NK cells obtained according to the preparation method in the present invention achieve low expression of CD7, and a suicide phenomenon of cells can be avoid...
|
|
WO/2022/188878A1 |
Provided is a multifunctional polypeptide, consisting of one or more of at least one Pro-Ala-Lys, Ala-Lys-Pro, Lys-Ala-Pro and a fragment thereof and a derived peptide, there being carnosine, anserine or ophidine at the C-terminus and/or...
|
|
WO/2022/188652A1 |
The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for p...
|
|
WO/2022/192634A1 |
In aspects, the invention provides novel compositions and methods for dominant inhibition of viral infection.
|
|
WO/2022/187865A1 |
A system for regulating protein dimerization kinetics is provided herein. The system includes a first polypeptide comprising a first alpha helix forming amino acid sequence configured to bind a second alpha helix forming amino acid seque...
|
|
WO/2022/184027A1 |
The present application relates to a novel coronavirus multivalent antigen, and a preparation method therefor and an application thereof. An amino acid sequence of the novel coronavirus antigen comprises: an amino acid sequence arranged ...
|
|
WO/2022/184015A1 |
The present application provides an antibody fusion protein and an application thereof. The antibody fusion protein has a high expression level, a high assembly rate, and high affinity, is convenient to purify and has good cytological ac...
|
|
WO/2022/186295A1 |
Provided is a method for artificially and efficiently inducing ectopic embryogenesis without fertilization in a seed plant. The present method includes introducing and expressing, in a seed plant, nucleic acid that includes a base sequen...
|
|
WO/2022/187583A1 |
The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.
|
|
WO/2022/186041A1 |
The purpose of the present invention is to provide a means for improving allergy test sensitivity. Provided is a chimeric FcεRI α-chain gene that contains a first base sequence encoding the extracellular domain of human FcεRI α-cha...
|
|
WO/2022/187584A1 |
The present disclosure relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer.
|
|
WO/2022/187496A1 |
Provided herein are, inter alia, a T-cell comprising a nucleic acid including a sequence encoding an anti-HIV Chimeric Antigen Receptor (CAR) and a sequence encoding a protein inhibitor. Methods for making the T-cells and for using the T...
|
|
WO/2022/178754A1 |
Provided are targeting conjugates comprising a targeting moiety, a therapeutic agent, and an oligonucleotide, wherein the oligonucleotide is attached to the targeting moiety via a targeting moiety binding fragment (TBF), wherein the ther...
|
|
WO/2022/180628A1 |
The present invention relates to fusion proteins comprising a proteinaceous therapeutic agent. Particularly, the present invention relates to fusion proteins comprising a two-domain carrier protein linked via a peptide linker to a protei...
|
|
WO/2022/179613A1 |
An immune effector cell expressing an exogenously introduced p40 subunit of IL-12; an exogenously introduced ligand of CCR7 (such as CCL-19 and CCL-21); and a functional exogenous receptor (such as a chimeric antigen receptor) comprising...
|
|
WO/2022/182294A1 |
The present invention lies in the technical field of enzymatic (poly)peptide ligation and specifically relates to methods that allow the ligation of (poly)peptides and oligonucleotides. The methods comprise providing at least one cargo m...
|
|
WO/2022/179004A1 |
A fusion protein with triple functions of tumor targeting, anti-CD3 and T-cell activation, and the use thereof. The trifunctional fusion protein comprises: an anti-tumor surface antigen (TAA) antibody part, an anti-CD3 antibody part, an ...
|
|
WO/2022/181550A1 |
The purpose of the present invention is to provide: an antibody capable of binding to N-protein of SARS-CoV-2; and a method for utilizing the antibody. Provided is an antibody capable of binding to SARS-CoV-2, which has at least one st...
|
|
WO/2022/178638A1 |
The present disclosure relates generally to the field of cancer immunotherapy. More particularly, the present disclosure provides antibody recruitment molecules, pharmaceutical compositions comprising same and kits comprising same. The p...
|
|
WO/2022/179552A1 |
The present invention relates to a modified neurotoxin single-chain polypeptide and a use thereof. The single-chain polypeptide contains a tagged protein, a linker short peptide, etc. The linker short peptide facilitates cleavage of the ...
|
|
WO/2022/182774A1 |
The present disclosure generally relates to, inter alia, chimeric antigen receptors (CARs) that contain an intracellular signaling domain without an immune receptor tyrosine based activation motif (ITAM). The disclosure also provides com...
|
|
WO/2022/179572A1 |
Provided are targeting conjugates comprising a targeting moiety, a therapeutic agent, and an oligonucleotide, wherein the oligonucleotide is attached to the targeting moiety via a targeting moiety binding fragment (TBF), wherein the ther...
|
|
WO/2022/181796A1 |
A site-specific modification method that enables isolation of a DNA molecule as a mutant clone. This method, for producing plant cells in which targeted sites of a double-stranded DNA are modified, involves: (i) a step for providing pl...
|
|
WO/2022/179039A1 |
Provided is a novel anti-human CD73 humanized antibody, which is capable of specifically binding to a CD73 antigen and has high affinity and biological activity.
|
